Drug Trial Radar · NCT01232556
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Last checked: Nov 20, 2026Latest source record: Jan 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
338
Actual
Start
Apr 4, 2011
Primary completion
Mar 28, 2014
Study completion Mar 28, 2014
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- UCB Pharma
- First posted
- Nov 2, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin plus rituximab in relapsed/refractory aggressive Non-Hodgkin lymphoma patients who are not candidates for intensive high-dose chemotherapy. Specifically, the goal is to demonstrate the superiority of this combination compared with an active comparator arm (investigator's choice of rituximab+bendamustine or rituximab+gemcitabine) using the primary endpoint of overall survival.
Conditions
- Lymphoma, Non-Hodgkin
Interventions
Inotuzumab ozogamicinDrug
1.8 mg/m2 on day 2 every 28 days by IV infusion, 3 to 6 cycles
RituximabDrug
375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles
rituximab + gemcitabineDrug
rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 to 6, every 28 days by IV infusion, 3 to 6 cycles; gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days, 3 to 6 cycles
rituximab +bendamustineDrug
rituximab 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles; bendamustine 120 mg/m2 on days 1 and 2 by IV infusion every 28 days, 3 to 6 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From randomization up to 5 years after last dose or up to final study visit, whichever occurs first.
- Percentage of Participants With a Treatment Emergent Adverse Event (TEAE) (Safety Population)Time frame: Up to 20 weeks after the first dose of study drug
Locations
177 sites in 25 countries. Site status is shown where the registry gives one.
Disney Family Cancer Center at Providence St Joseph Medical Center
Burbank, California
Providence St Joseph Medical Center
Burbank, California
Hematology-Oncology Medical Group of Fresno Inc
Fresno, California
Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services
Los Angeles, California
Clinical Research Unit
Los Angeles, California
Peter Morton Medical Plaza
Los Angeles, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
Sansum Clinic
Santa Barbara, California
UCLA Santa Monica Hematology Oncology
Santa Monica, California
Sansum Clinic
Solvang, California
Howard University Hospital
Washington D.C., District of Columbia
Mount Sinai Comprehensive Cancer Center at Aventura
Aventura, Florida
University Cancer Institute
Boynton Beach, Florida
21st Century Oncology of Jacksonville, LLC
Fernandina Beach, Florida
Davis Cancer Pavilion and Shands Medical Plaza
Gainesville, Florida
Shands Cancer Hospital at the University of Florida
Gainesville, Florida
UF Health Davis Cancer Pavillion and Shands Med Plaza
Gainesville, Florida
UF Health Shands Cancer Hospital
Gainesville, Florida
Shands Hospital at the University of Florida
Gainesville, Florida
UF Health Shands Hospital
Gainesville, Florida
21st Century Oncology of Jacksonville, LLC
Jacksonville, Florida
21st Century Oncology of Jacksonville, LLC
Jacksonville, Florida
Baptist Cancer Institute
Jacksonville, Florida
Baptist Medical Center
Jacksonville, Florida
21st Century Oncology of Jacksonville, LLC
Jacksonville, Florida
21st Century Oncology of Jacksonville, Inc.
Jacksonville, Florida
Medical Specialists Of The Palm Beaches
Lake Worth, Florida
Advanced Medical Specialties
Miami, Florida
Mercy Hospital
Miami, Florida
Mercy Research Institute
Miami, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Mount Sinai Medical Center
Miami Beach, Florida
21st Century Oncology of Jacksonville, LLC
Orange Park, Florida
Georgia Regents Medical Cancer Pharmacy
Augusta, Georgia
Georgia Regents University
Augusta, Georgia
Kootenai Cancer Center
Coeur d'Alene, Idaho
Kootenai Cancer Center
Post Falls, Idaho
Decatur Memorial Hospital (DMH)
Decatur, Illinois
Floyd Memorial Cancer Center of Indiana
New Albany, Indiana
University of Kansas Medical Center
Kansas City, Kansas
Showing 40 of 177 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.